Hyperglycaemia-induced chemoresistance of prostate cancer cells due to IGFBP2

Endocrine-Related Cancer

Volumn 20, Issue 5, 2013, Pages 741-751

  Biernacka, K M ^a   Uzoh, C C ^a,b   Zeng, L ^a   Persad, R A ^b   Bahl, A ^c   Gillatt, D ^b   Perks, C M ^a   Holly, J M P ^a  

^a School of Clinical Sciences at North Bristol   (United Kingdom)

^b SOUTHMEAD HOSPITAL   (United Kingdom)

^c BRISTOL HAEMATOLOGY AND ONCOLOGY CENTRE   (United Kingdom)

Author keywords

Carcinoma; Chemotherapy; IGF; Obesity; Prostate

Indexed keywords

DOCETAXEL; GLUCOSE; HISTONE H3; HISTONE H4; SMALL INTERFERING RNA; SOMATOMEDIN BINDING PROTEIN 2;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CELL DEATH; CELL STRAIN; CELL STRAIN DU145; CELL STRAIN LNCAP; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DNA METHYLATION; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; EPIGENETIC REPRESSION; GENE SILENCING; GLUCOSE BLOOD LEVEL; HISTONE ACETYLATION; HUMAN; HUMAN CELL; HYPERGLYCEMIA; IMMUNOBLOTTING; MALE; PC3 CELL; PROMOTER REGION; PROSTATE CANCER; THERAPY; UPREGULATION;

EID: 84886377083     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-13-0077     Document Type: Article

References (36)

1. Ambrosini-Spaltro A, Farnedi A, Montironi R & Foschini MP 2011 IGFBP2 as an immunohistochemical marker for prostatic adenocarcinoma. Applied Immunohistochemistry & Molecular Morphology 19 318-328. (doi:10.1097/PAI. 0b013e3128052936)
2. Bach LA, Headey SJ & Norton RS 2005 IGF-binding proteins - the pieces are falling into place. Trends in Endocrinology and Metabolism 16 228-234. (doi:10.1016/j.tem.2005.05.005)
3. Chatterjee S, Park ES & Soloff MS 2004 Proliferation of DU145 prostate cancer cells is inhibited by suppressing insulin-like growth factor binding protein-2. International Journal of Urology 11 876-884. (doi:10.1111/j.1442-2042.2004.00898.x)
4. Chen Z, Lu W, Garcia-Prieto C & Huang P 2007 The Warburg effect and its cancer therapeutic implications. Journal of Bioenergetics and Biomembranes 39 267-274. (doi:10.1007/s10863-007-9086-x)
5. Davies SC, Wass JA, Ross RJ, Cotterill AM, Buchanan CR, Coulson VJ & Holly JM 1991 The induction of a specific protease for insulin-like growth factor binding protein-3 in the circulation during severe illness. Journal of Endocrinology 130 469-473. (doi:10.1677/joe.0.1300469)
6. Davis LK, Rodgers BD & Kelley KM 2008 Angiotensin II- and glucosestimulated extracellular matrix production: mediation by the insulin-like growth factor (IGF) axis in a murine mesangial cell line. Endocrine 33 32-39. (doi:10.1007/s12020-008-9055-0)
7. Degraff DJ, Aguiar AA & Sikes RA 2009 Disease evidence for IGFBP-2 as a key player in prostate cancer progression and development of osteosclerotic lesions. American Journal of Translational Research 1 115-130.
8. Friis RM, Wu BP, Reinke SN, Hockman DJ, Sykes BD & Schultz MC 2009 A glycolytic burst drives glucose induction of global histone acetylation by picNuA4 and SAGA. Nucleic Acids Research 37 3969-3980. (doi:10.1093/nar/gkp270)
9. Gan L, Han Y, Bastianetto S, Dumont Y, Unterman TG & Quirion R 2005 FoxO-dependent and -independent mechanisms mediate SirT1 effects on IGFBP-1 gene expression. Biochemical and Biophysical Research Communications 337 1092-1096. (doi:10.1016/j.bbrc.2005. 09.169)
10. Gribovskaja-Rupp I, Kosinski L & Ludwig KA 2011 Obesity and colorectal cancer. Clinics in Colon and Rectal Surgery 24 229-243. (doi:10.1055/ s-0031-1295686)
11. Hammarsten J & Hogstedt B 2004 Clinical, haemodynamic, anthropometric, metabolic and insulin profile of men with high-stage and high-grade clinical prostate cancer. Blood Pressure 13 47-55. (doi:10.1080/08037050310025735)
12. Hammarsten J & Hogstedt B 2005 Hyperinsulinaemia: a prospective risk factor for lethal clinical prostate cancer. European Journal of Cancer 41 2887-2895. (doi:10.1016/j.ejca.2005.09.003)
13. Heald AH, Kaushal K, Siddals KW, Rudenski AS, Anderson SG & Gibson JM 2006 Insulin-like growth factor binding protein-2 (IGFBP-2) is a marker for the metabolic syndrome. Experimental and Clinical Endocrinology & Diabetes 114 371-376. (doi:10.1055/s-2006-924320)
14. Hiraoka D, Yoshida W, Abe K, Wakeda H, Hata K & Ikebukuro K 2012 Development of a method to measure DNA methylation levels by using methyl CpG-binding protein and luciferase-fused zinc finger protein. Analytical Chemistry 84 8259-8264. (doi:10.1021/ac3015774)
15. Jeronimo C, Bastian PJ, Bjartell A, Carbone GM, Catto JW, Clark SJ, Henrique R, Nelson WG & Shariat SF 2011 Epigenetics in prostate cancer: biologic and clinical relevance. European Urology 60 753-766. (doi:10.1016/j.eururo.2011.06.035)
16. Jiralerspong S, Palla SL, Giordano SH, Meric-Bernstam F, Liedtke C, Barnett CM, Hsu L, Hung MC, Hortobagyi GN & Gonzalez-Angulo AM 2009 Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. Journal of Clinical Oncology 27 3297-3302. (doi:10.1200/JCO.2009.19.6410)
17. Kasper JS & Giovannucci E 2006 A meta-analysis of diabetes mellitus and the risk of prostate cancer. Cancer Epidemiology, Biomarkers & Prevention 15 2056-2062. (doi:10.1158/1055-9965.EPI-06-0410)
18. Liu X, Ji J, Sundquist K, Sundquist J & Hemminki K 2012 The impact of type 2 diabetes mellitus on cancer-specific survival: a follow-up study in Sweden. Cancer 118 1353-1361. (doi:10.1002/cncr.26420)
19. Martin RM, Holly JM, Davey Smith G & Gunnell D 2006 Associations of adiposity from childhood into adulthood with insulin resistance and the insulin-like growth factor system: 65-year follow-up of the Boyd Orr Cohort. Journal of Clinical Endocrinology and Metabolism 91 3287-3295. (doi:10.1210/jc.2006-0745)
20. Maskarinec G & Noh JJ 2004 The effect of migration on cancer incidence among Japanese in Hawaii. Ethnicity & Disease 14 431-439.
21. Monti S, Proietti-Pannunzi L, Sciarra A, Lolli F, Falasca P, Poggi M, Celi FS & Toscano V 2007 The IGF axis in prostate cancer. Current Pharmaceutical Design 13 719-727. (doi:10.2174/138161207780249128)
22. Nakazawa K, Kurishima K, Tamura T, Ishikawa H, Satoh H & Hizawa N 2013 Survival difference in NSCLC and SCLC patients with diabetes mellitus according to the first-line therapy. Medical Oncology 30 367. (doi:10.1007/s12032-012-0367-9)
23. Nishimura A, Fujimoto M, Oguchi S, Fusunyan RD, MacDermott RP & Sanderson IR 1998 Short-chain fatty acids regulate IGF-binding protein secretion by intestinal epithelial cells. American Journal of Physiology 275 E55-E63.
24. O'Neill AJ, Prencipe M, Dowling C, Fan Y, Mulrane L, Gallagher WM, O'Connor D, O'Connor R, Devery A, Corcoran C et al. 2011 Characterisation and manipulation of docetaxel resistant prostate cancer cell lines. Molecular Cancer 10 126. (doi:10.1186/1476-4598- 10-126)
25. Roddam AW, Allen NE, Appleby P, Key TJ, Ferrucci L, Carter HB, Metter EJ, Chen C, Weiss NS, Fitzpatrick A et al. 2008 Insulin-like growth factors, their binding proteins, and prostate cancer risk: analysis of individual patient data from 12 prospective studies. Annals of Internal Medicine 149 461-471 (W83-88) (doi:10.7326/0003-4819-149-7-200810070-00006)
26. Saylor PJ & Smith MR 2009 Metabolic complications of androgen deprivation therapy for prostate cancer. Journal of Urology 181 1998-2006 (discussion 2007-2008) (doi:10.1016/j.juro.2009.01.047)
27. Schayek H, Bentov I, Sun S, Plymate SR & Werner H 2010 Progression to metastatic stage in a cellular model of prostate cancer is associated with methylation of the androgen receptor gene and transcriptional suppression of the insulin-like growth factor-I receptor gene. Experimental Cell Research 316 1479-1488. (doi:10.1016/j.yexcr.2010. 03.007)
28. Sharifi N, Gulley JL & Dahut WL 2005 Androgen deprivation therapy for prostate cancer. Journal of the AmericanMedical Association 294 238-244. (doi:10.1001/jama.294.2.238)
29. Taylor LG, Canfield SE & Du XL 2009 Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer. Cancer 115 2388-2399. (doi:10.1002/cncr.24283)
30. Thomas F, Holly JM, Persad R, Bahl A & Perks CM2010 Fibronectin confers survival against chemotherapeutic agents but not against radiotherapy in DU145 prostate cancer cells: involvement of the insulin like growth factor-1 receptor. Prostate 70 856-865. (doi:10.1002/pros.21119)
31. Uzoh CC, Perks CM, Bahl A, Holly JM, Sugiono M & Persad RA 2009 PTEN-mediated pathways and their association with treatmentresistant prostate cancer. BJU International 104 556-561. (doi:10.1111/ j.1464-410X.2009.08411.x)
32. Uzoh CC, Holly JM, Biernacka KM, Persad RA, Bahl A, Gillatt D & Perks CM 2011 Insulin-like growth factor-binding protein-2 promotes prostate cancer cell growth via IGF-dependent or -independent mechanisms and reduces the efficacy of docetaxel. British Journal of Cancer 104 1587-1593. (doi:10.1038/bjc.2011.127)
33. Xiong Z & Laird PW 1997 COBRA: a sensitive and quantitative DNA methylation assay. Nucleic Acids Research 25 2532-2534. (doi:10.1093/ nar/25.12.2532)
34. Wiley A, Katsaros D, Fracchioli S & Yu H 2006 Methylation of the insulinlike growth factor binding protein-3 gene and prognosis of epithelial ovarian cancer. International Journal of Gynecological Cancer 16 210-218. (doi:10.1111/j.1525-1438.2006.00299.x)
35. Zeng L, Biernacka KM, Holly JM, Jarrett C, Morrison AA, Morgan A, Winters ZE, Foulstone EJ, Shield JP & Perks CM 2010 Hyperglycaemia confers resistance to chemotherapy on breast cancer cells: the role of fatty acid synthase. Endocrine-Related Cancer 17 539-551. (doi:10.1677/ ERC-09-0221)
36. Zhou JA,McIndoe A, Davies H, Sun XY & Crawford L 1991 The induction of cytotoxic T-lymphocyte precursor cells by recombinant vaccinia virus expressing human papillomavirus type 16 L1. Virology 181 203-210. (doi:10.1016/0042-6822(91) 90485-T)